Publications

Logan A, Berube C, Gotlib J. Accessory splenules in autoimmune hemolytic anemia. American journal of hematology. 2012. PMID: 23027373


Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN (National Comprehensive Cancer Network). Non-small cell lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2012. PMID: 23054877


Vijayaraghavan M, Tochterman A, Hsu E, Johnson K, Marcus S, Caton CL. Health, access to health care, and health care use among homeless women with a history of intimate partner violence. Journal of community health. 2012. PMID: 22187095


Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. American journal of clinical oncology. 2012. PMID: 21552099


Shah NP. Front-line TKI therapy for chronic-phase CML: the luxury of choice. Oncology (Williston Park, N.Y.). 2012. PMID: 23175996


Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England journal of medicine. 2012. PMID: 23020132


Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer chemotherapy and pharmacology. 2012. PMID: 23053263


Orr N, Lemnrau A, Cooke R, Fletcher O, Tomczyk K, Jones M, Johnson N, Lord CJ, Mitsopoulos C, Zvelebil M, McDade SS, Buck G, Blancher C, KConFab Consortium, Trainer AH, James PA, Bojesen SE, Bokmand S, Nevanlinna H, Mattson J, Friedman E, Laitman Y, Palli D, Masala G, Zanna I, Ottini L, Giannini G, Hollestelle A, Ouweland AM, Novakovic S, Krajc M, Gago-Dominguez M, Castelao JE, Olsson H, Hedenfalk I, Easton DF, Pharoah PD, Dunning AM, Bishop DT, Neuhausen SL, Steele L, Houlston RS, Garcia-Closas M, Ashworth A, Swerdlow AJ. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nature genetics. 2012. PMID: 23001122


Komanduri KV. GVHD protection? ThiNK iNKT cells. Blood. 2012. PMID: 22956529


Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012. PMID: 22955915


de Cerio AL, Inogés S, Ai WZ, Villanueva H, Pastor F, Soldevilla MM, Soria E, Bendandi M. Successful idiotypic vaccination following stem cell allotransplant in lymphoma. Leukemia & lymphoma. 2012. PMID: 22897725


Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. Journal of immunology (Baltimore, Md. : 1950). 2012. PMID: 22956585


Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012. PMID: 22949151


Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast cancer research and treatment. 2012. PMID: 22941572


Bajrami I, Kigozi A, Van Weverwijk A, Brough R, Frankum J, Lord CJ, Ashworth A. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO molecular medicine. 2012. PMID: 22933245


Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU international. 2012. PMID: 22928480


Logan AC, Weissman IL, Shizuru JA. The road to purified hematopoietic stem cell transplants is paved with antibodies. Current opinion in immunology. 2012. PMID: 22939368


Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, d'Amore ES, Li Y, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Wang HY, Dunphy CH, His ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Ai W, O'Neill S, Ponzoni M, Ferreri AJ, Kahl BS, Winter JN, Go RS, Dirnhofer S, Piris MA, Møller MB, Wu L, Medeiros LJ, Young KH. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2012. PMID: 22929980


Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, Faham M, Dahl G, Lacayo N. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012. PMID: 22932801